Introduction
Meningococcal disease is a potentially devastating infection that fortunately is relatively rare among US adults. The currently available vaccine, directed against meningococcal serogroups A, C, Y, and W135, is not recommended for routine use in the United States but is recommended for certain high-risk groups.1 Recently, reports of sporadic cases as well as of outbreaks2'3 of serogroup C meningococcal disease on US college campuses have raised concern that college students may have an elevated risk of acquiring meningococcal disease. This has prompted consideration of whether this group should be targeted for routine vaccination. Accordingly, a cost-benefit analysis was performed to assess the potential economic effect of such a program.
Methods
The following estimates were used to calculate the number of cases of meningococcal disease that would occur, both with and without a program of vaccination on college entry, over a 4-year period. The annual number of entering freshmen was estimated to be 2.3 million (unpublished data, American Council on Education). rate among 18-to 22-year-olds. Based on surveillance data, we estimate the maximum possible rate of disease among college students to be 1.3/100 000 population, or 2.6 times our baseline rate. At rates of disease near this estimate, the annual net cost of a strategy ofvaccination approximates $45 million. Although the vaccine is efficacious, savings in treatment and premature death costs resulting from prevention of this relatively rare disease are small compared with the substantial cost of immunizing more than 2 million students annually. If a prevention strategy is shown to be cost-effective, there is usually little debate over whether it should be implemented since it will ultimately conserve resources. However, a measure does not necessarily have to be cost-effective before it can be recommended for implementation. The decision of whether to implement a measure that prevents disease but requires net spending is more complex and may be influenced by factors such as the magnitude of the cost of the intervention, the intervention's acceptability, and the priority assigned to prevention of disease, as well as by the value assigned to more intangible factors, such as pain and grief suffered as a result of disease.
Our analysis raises the issue of whether a program of routine vaccination of college students against meningococcal disease would be an efficient use of health care resources. However, vaccination is still indicated for control of serogroup C outbreaks, a situation in which one-time vaccination of a defined high-risk group is likely to prevent additional cases. Further studies to identify a subset of students at substantially elevated risk of disease, or the development of a conjugate serogroup C meningococcal vaccine that could be administered during infancy to confer long-lasting protection, may allow development of more cost-effective strategies for the prevention of meningococcal disease in the United States. O
